Brickstream Corporation announces OEM Partnership with Human Recognition Systems Ltd.

Brickstream Corporation is pleased to announce that they have signed a reseller agreement with Human Recognition Systems Limited (HRS), which will allow HRS to represent and sell Brickstream’s market leading, ClarityTM Video Analytic Appliance

Atlanta, GA – 05th September 2008 – BRICKSTREAM CORPORATION - a leader in intelligent Video Analytics, announces a strategic OEM Reseller Partnership with Human Recognition Systems Ltd. To add the leading Clarity intelligent video analytics appliance to their current people and behaviour monitoring systems. Read more: Brickstream Corporation announces OEM Partnership with Human Recognition Systems

Nebu Resources and Exploration Partner Quest Uranium Discover Extensive Uranium Zones on Recently Optioned Stewart Lake and Nanuk Properties on George River, Northeastern Quebec

Highlights:
- Prospectors have discovered new areas of uranium mineralization on the Nanuk property, forming part of a single, extensive zone measuring 50 to 500 metres wide and at least 2.0 kilometres in strike length
- A diamond drill has been mobilized to the area and drilling has commenced to test the continuity of the zone
- Mapping, prospecting and line-cutting crews have been in the project area since mid-July to conduct advanced exploration of known uranium mineralized zones and to evaluate new, high-potential targets

Nebu Resources Inc. (TSX VENTURE:NBU) in conjunction with exploration partner Quest Uranium (TSX VENTURE:QUC), is pleased to announce that ground crews have identified a continuous zone of uranium mineralization on the recently optioned Nanuk property. Read more: Nebu Resources Inc ( NBU )

BioMS Medical\'s lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company\'s lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

Fast track designation is an FDA status reserved for products that are intended to treat a serious or life-threatening condition and that demonstrate the potential to address unmet medical needs for that condition. Fast track designation can potentially facilitate development and expedite the review process. Read more: BioMS Medical Corp ( MS )

BRC DiamondCore sixth open tender of 1,351.13 carats realises US$1,365,736 First production from third trial mining project, De Kalk

BRC DiamondCore Ltd. (the \"Company\") (TSX - BCD; JSE - BCD) is pleased to announce that diamonds totaling 1,351.13 carats from the Company\'s Silverstreams alluvial, De Kalk alluvial and Paardeberg East kimberlite trial mining projects in South Africa\'s Northern Cape Province were sold at the Company\'s sixth tender and realised US$1,365,736.

This compares with US$992,555 realised from the sale of stones totalling 959.46 carats from the Silverstreams and Paardeberg East projects at the Company\'s previous tender.

The latest tender includes, for the first time, stones produced from the Company\'s De Kalk alluvial trial mining project. De Kalk is the site of the discovery of the first diamond in South Africa, the 24-carat Eureka, in 1866. Read more: BRC DiamondCore Ltd ( BCD )